Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pneumococcal Polysaccharide Vaccine (PPSV23) is available for free in some Chinese cities for elderly patients and those with comorbidities. However, there is a lack of studies summarizing its preventive effect specifically in Chinese adults. This review aims to discuss the epidemiology of pneumococcal disease, coverage and effectiveness of PPSV23 vaccination, elderly individuals and patients with comorbidities, coadministration of PPSV23 vaccine with other vaccines, and future directions for its use in China. It was found that the PPSV23 vaccination rate among the elderly ranged from 1.2% to 42.1% depending on location, with an effectiveness of 9.34%(95%CI: 2.05%, 16.62%) to 57.7%(95%CI: 20.7%, 77.5%). There is a need to raise awareness of pneumococcal disease and its prevention, especially in China. To better manage pneumococcal disease in China, developing new vaccines for common serotypes and continuously monitoring serotype distribution associated with the disease is also needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21645515.2024.2440955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus.
Lupus Sci Med
September 2025
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background: SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.
View Article and Find Full Text PDFPay-It-Forward 23-Valent Pneumococcal Polysaccharide Vaccination Among Older Adults: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health & Life Science Institute, Guangxi Medical University, Nanning, China.
Background: The 23-valent pneumococcal polysaccharide vaccine reduces the risk of pneumonia among adults by 38% to 46%. However, only a few older adults in resource-limited areas of China have received the pneumococcal vaccination. Pay-it-forward is a social innovation that offers participants free or subsidized health services and a community-engaged message, with an opportunity to donate to support subsequent recipients.
View Article and Find Full Text PDFErratum for "Association Between Introduction of the 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) and Pneumonia Incidence and Mortality Among General Older Population in Japan: A Community-based Study."J Epidemiol 35(5) (2025) 237-244.
J Epidemiol
September 2025
Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.
Biochemical and Immunological Insights into Capsular Polysaccharide of Serotype 38 (American Type 71)An Emerging Nonvaccine Serotype.
ACS Omega
August 2025
Department of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Medchal District, Telangana 500078, India.
Invasive pneumococcal disease presents a threat to humankind, predominantly affecting children and the elderly. Despite the availability of high-valency pneumococcal polysaccharide vaccine of PPSV23 (PNEUMOVAX 23) and conjugate vaccines such as VAXNEUVANCE and PREVNAR 20, nonvaccine serotypes continue to contribute to higher mortality rates. The characterization of nonvaccine serotypes is becoming increasingly crucial considering an increase in their prevalence.
View Article and Find Full Text PDFImmune Reconstitution and Need for Booster Vaccinations Among Non-Transplant Childhood Cancer Survivors: A Single-Center Experience.
Cancer Rep (Hoboken)
September 2025
Baylor College of Medicine, Houston, Texas, USA.
Background: Waning immunity from childhood vaccines can be more profound in pediatric patients following chemo/immunotherapy. Moreover, childhood cancer survivors (CCS) are at significantly increased risk for life-threatening infections. We implemented an institutional standard of practice (SOP) to assess immune reconstitution and provide recommendations for re-vaccination for non-transplant CCS.
View Article and Find Full Text PDF